BioMarin Takes One Step Closer To Profitability With Positive GALNS Data
This article was originally published in The Pink Sheet Daily
Executive Summary
The orphan drug company reported positive Phase III data on its candidate for patients with the rare disease MPS IV and expects to file GALNS for FDA approval in the first quarter.
You may also be interested in...
BioMarin: A Rare Disease Specialist With An Eye On The Long-Term
BioMarin is in the midst of a pivotal year, with several near-term data catalysts, the most important of which will be Phase III data on GALNS for the rare disease MPS IV.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.